The XRCC3 Thr241Met Polymorphism Influences Glioma Risk - A Meta-analysis

Abstract

Background: Findings from previous published studies regarding the association of the XRCC3 Thr241Met polymorphism with glioma susceptibility have often been conflicting. Therefore, a meta-analysis including all available publications was carried out to make a more precise estimation of the potential relationship. Methods: By searching the electronic databases of Pubmed and Embase (up to April 1st, 2013), a total of nine case-control studies with 3,752 cases and 4,849 controls could be identified for inclusion in the current meta-analysis. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of the association. Results: This meta-analysis showed the XRCC3 Thr241Met polymorphism to be significantly associated with decreased glioma risk in the allelic model (Met allele vs. Thr allele: OR= 0.708, 95%CI= 0.631-0.795). Moreover, we also observed a statistically significant association between the XRCC3 Thr241Met polymorphism and reduced glioma risk in analyses stratified by ethnicity (Asian) and source of controls (hospital based) in the allelic model. Conclusions: Current evidence suggests that the XRCC3 Thr241Met polymorphism may be a risk factor for glioma development, especially in Asians.

Lack of Influence of an XRCC3 Gene Polymorphism on Oral Cancer Susceptibility: Meta-analysis

“…Although this meta-analysis did not show the significant association between XRCC3 rs861539 polymorphism and oral cancer risks, the present results also provided new evidence for the susceptibility and etiology of oral cancer. In recent years, there are some meta-analyses about XRCC3 polymorphisms and cancer risks, which comprised breast cancer, cervical cancer, colorectal cancer, gliomas and head and neck caner published in the journal Asian Pac J Cancer Prev and the results are not concordant, suggesting this polymorphism plays different role in diverse types of cancer (Yin et al, 2012;Jiang et al, 2013;Nassiri et al, 2013;Qin et al, 2013;Mao et al, 2014). It is well known that systematic review and meta-analyses are considered the highest level of evidence in Evidencebased Medicine.…”

DNA repair gene XRCC3 Thr241Met polymorphism and susceptibility to glioma: A case-control study

“…A meta-analysis of 11 case-control studies with 2,404 glioma cases and 6,379 control subjects found that the risk of glioma significantly increased between the GSTP1 A114V genotype and other histopathological gliomas, not including glioblastoma multiforme (27). A meta-analysis of nine case-control studies with 3,146 cases and 4,296 control subjects indicated that the XRCC1 Arg399Gln polymorphism was associated with an increased risk of glioma among Asian individuals and borderline increased risk for glioblastoma among Caucasian individuals, whereas the XRCC1 Arg194Trp/Arg280His polymorphisms may have no affect on the susceptibility of glioma among different ethnicities (24). A systematic literature review and meta-analysis of six case-control studies with 2,362 glioma cases and 3,085 control subjects did not indicate a major role of the XRCC1 Arg399Gln polymorphism in influencing the risk of glioma among Caucasian individuals (28).…”

“…Although the association between the XRCC3 Thr241Met polymorphism and glioma risk have been extensively investigated, the currently available results are inconclusive (18–24). Although two meta-analyses have been conducted to investigate this association, conflicting results were yielded (23,24).…”

“…Although two meta-analyses have been conducted to investigate this association, conflicting results were yielded (23,24). The present study aimed to investigate the association between the XRCC3 Thr241Met polymorphism and the susceptibility to glioma.…”

Comprehensive Analysis of Temozolomide Treatment for Patients with Glioma

“…Gliomas are the most common malignant brain tumors in Chinese adults (Cheng et al, 2013;Ge et al, 2013;Jiang et al, 2013;Liang et al, 2013;Yu et al, 2013;Luo et al, 2013;Zhu et al, 2013). Previous report revealed a statistically significant survival benefit for patients with gliomas treated with radiotherapy (RT) plus concomitant and adjuvant temozolomide (TMZ) chemotherapy, which currently represents the standard of care for newly diagnosed gliomas Stupp et al, 2007;Stupp et alk., 2009).…”